Yi Jin
Chief Executive Officer GeCell Therapeutics
Bachelor of Sichuan University, Ph.D. of Iowa State University, Poor Postdoctoral University of California, Berkeley
Yi Jin has more than 20 years of academic research and enterprise research and development experience, including the University of California, Berkeley, Bayer, Kingsley and other internationally renowned institutes, large pharmaceutical companies and CROs. She focuses on tumor immunity, autoimmune, single-gene genetic diseases, etc., and has rich early research and preclinical development experience, including promoting technology platform construction. In terms of academic research, there are dozens of academic papers in academic research in journals such as Cell, Molecular Cell, Development Cell, J. Cell Biol., J. Cell. BioChem. She has rich team management capabilities, including multi-disciplinary and cross-professional team management, especially early R & D, transformation of medicine and preclinical pharmacy, such as CMC, QA/QC, etc.
Seminars
Achieving durable responses in patients remains one of the most important challenges for NK cell therapies. This panel will bring together leaders in academia, biotech, and clinical development to discuss strategies for boosting efficacy, extending persistence, and improving the therapeutic potential of NK-based treatments. Experts will explore how next generation engineering, manufacturing, and clinical insights are shaping the future of innate cell therapies.
- Understanding barriers to efficacy and persistence, examining tumor escape, immunosuppression, and NK cell exhaustion that limit clinical outcomes
- Advancing engineering solutions, exploring cytokine support, gene edits, and checkpoint resistance to strengthen NK cell function in vivo
- Improving translation to the clinic, aligning manufacturing, trial design, and biomarker strategies to achieve more consistent and durable responses
A dynamic opening discussion featuring CEOs and founders at the forefront of innate immunity and NK-cell innovation. This high-level session sets the tone for the meeting as industry leaders examine the current landscape, emerging scientific and commercial inflection points, and the path to translating innate immune breakthroughs into meaningful therapeutic impact. Through candid insights and forward-looking perspectives, the panel will outline the opportunities, challenges, and decisive moves that will shape the field over the next 3–5 years.
- The milestones that brought innate therapies to today’s inflection point
- What’s driving the next wave of NK and innate innovation
- Scientific and clinical hurdles that must be overcome
- Strategic priorities in a shifting funding and regulatory climate
- Commercial pathways and competitive positioning for the next era
